Document Detail

Better data needed from pregnancy registries.
MedLine Citation:
PMID:  19107958     Owner:  NLM     Status:  MEDLINE    
This article is a consensus position statement from the Research Committee of the Organization of Teratology Information Specialists (OTIS). The Committee believes that more specific information on the timing and dose of drug exposures from pregnancy birth defect registries sponsored by pharmaceutical companies (herein called pregnancy registries) would improve the estimation of risk for developmental toxicity (i.e., growth alteration, structural anomalies, functional/neurobehavioral deficits, or death). Specifically, the Committee believes that the exposure timing should be stated in gestational weeks and days rather than simply weeks. In addition, the Committee believes that the exposure dose should be stated in patient-specific terms, such as body weight (mg/kg) or body surface area (mg/m(2)) rather than simply dose strength. Although the focus of this position is pregnancy registries, it also is applicable to any source of medication-induced embryo-fetal toxicity.
Gerald G Briggs; Janine Polifka;
Related Documents :
15609968 - Al-isopropoxydiisobutylalane: a study of the effect of solvent on the rate and stereose...
15106858 - Endotoxin exposure in utero increases ethanol consumption in adult male offspring.
1742388 - Coffee consumption, birthweight, and reproductive failures.
15749258 - Pregnancy outcome after exposure to ranitidine and other h2-blockers. a collaborative s...
22399208 - Yoga during pregnancy: a review.
17694578 - Treatment with amniopatch of premature rupture of membranes after first-trimester chori...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Birth defects research. Part A, Clinical and molecular teratology     Volume:  85     ISSN:  1542-0760     ISO Abbreviation:  Birth Defects Res. Part A Clin. Mol. Teratol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-12     Completed Date:  2009-04-14     Revised Date:  2013-05-06    
Medline Journal Info:
Nlm Unique ID:  101155107     Medline TA:  Birth Defects Res A Clin Mol Teratol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  109-11     Citation Subset:  IM    
Copyright Information:
(c) 2008 Wiley-Liss, Inc.
Perinatal Support Service, MemorialCare Center for Women, Miller Children's Hospital, Long Beach Memorial Medical Center, Long Beach, CA 90806, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / epidemiology*
Congenital Abnormalities / epidemiology*,  etiology
Dose-Response Relationship, Drug
Pharmaceutical Preparations / adverse effects*
Prenatal Exposure Delayed Effects / chemically induced,  epidemiology
Product Surveillance, Postmarketing / methods,  standards
Risk Factors
Time Factors
Grant Support
Reg. No./Substance:
0/Pharmaceutical Preparations
Elizabeth Balken / ; Anick Berard / ; Stephen Braddock / ; Gerald Briggs / ; Christina Chambers / ; Adrienne Einarson / ; Cecilia Lyons Gaffaney / ; Mara Gaudette / ; Gideon Koren / ; Kenneth Jones / ; Steve Lamm / ; Richard Miller / ; Janine Polifka / ; Sara Riordan / ; Luther Robinson / ; Offie Soldin / ; Katherine Wisner / ; Lori Wolfe /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical geneticists in birth defects surveillance and epidemiology research programs: past, present...
Next Document:  DSCG reduces RSV-induced illness in RSV-infected mice.